You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Venclyxto

Showing 1 - 25 of 115
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

AML, MDS Trial in Tuebingen (Decitabine, Venetoclax)

Recruiting
  • AML
  • MDS
  • Tuebingen, Baden-Wuerttemberg, Germany
    University Hospital
Nov 30, 2023

Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma Trial (Ibrutinib, Venetoclax)

Not yet recruiting
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Small Lymphocytic Lymphoma
  • (no location specified)
Jul 19, 2023

Acute Myeloid Leukemia, MDS Trial in Hangzhou (Decitabine for Injection, VENCLYXTO)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
  • Decitabine for Injection
  • VENCLYXTO
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, College of Medicine, Zhejiang Uni
Sep 18, 2023

Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma Trial in Boston (CB-103,

Not yet recruiting
  • Adenoid Cystic Carcinoma
  • +2 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Mar 14, 2023

Waldenstrom Macroglobulinemia, B-Cell Lymphoproliferative Disorder Trial in Boston (Pirtobrutinib, Venetoclax, Allopurinol)

Not yet recruiting
  • Waldenstrom Macroglobulinemia
  • B-Cell Lymphoproliferative Disorder
  • Boston, Massachusetts
  • +2 more
Feb 18, 2023

Chronic Lymphocytic Leukemia Trial in Houston (Ibrutinib, Venetoclax)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
Sep 21, 2022

Acute Myeloid Leukemia, MDS, Chronic Myelomonocytic Leukemia Trial in Houston (DSP107, Azacitidine, Venetoclax)

Recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • DSP107
  • +2 more
  • Houston, Texas
    The University of Texas MD Anderson Cancer Center, Department of
Nov 13, 2022

Leukemia, Myeloid, Acute Trial in Guanzhou (Azacitidine, Venetoclax)

Not yet recruiting
  • Leukemia, Myeloid, Acute
  • Guanzhou, Guandong, China
    Nanfang Hospital of Southern Medical University
Jul 22, 2022

Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia Trial in

Not yet recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 10, 2023

Real World Outcomes Using Novel Agents for AML in the UK

Not yet recruiting
  • Acute Myeloid Leukemia
  • London, United Kingdom
    Guy's and St Thomas' NHS Foundation Trust
Mar 28, 2022

Secondary Myelodysplastic Syndrome, Therapy-Related Myelodysplastic Syndrome Trial in Columbus (Azacitidine, Quality-of-Life

Recruiting
  • Secondary Myelodysplastic Syndrome
  • Therapy-Related Myelodysplastic Syndrome
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Dec 1, 2022

Acute Myeloid Leukemia in Remission, FLT3 Gene Mutation, Hematologic and Lymphocytic Disorder Trial in Houston (Azacitidine,

Recruiting
  • Acute Myeloid Leukemia in Remission
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 13, 2022

Chronic Lymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in Houston

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 12, 2022

Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Duarte (8-Chloroadenosine,

Recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • Duarte, California
    City of Hope Medical Center
Aug 15, 2022

Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia Trial in Houston (Decitabine, Quizartinib,

Recruiting
  • Acute Myeloid Leukemia
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 27, 2023

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Atlanta (Tocilizumab, Venetoclax)

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Jan 24, 2023

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Columbus (Acalabrutinib, Obinutuzumab, Venetoclax)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Nov 2, 2022

Primary CNS Lymphoma Trial in Stuttgart (Venetoclax, Obinutuzumab)

Terminated
  • Primary CNS Lymphoma
  • Stuttgart, Baden-Württemberg, Germany
    Klinikum Stuttgart
Jan 18, 2022

Acute Myeloid Leukemia Trial in Sacramento (Azacitidine, Uproleselan, Venetoclax)

Recruiting
  • Acute Myeloid Leukemia
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Aug 12, 2022

Untreated Myelodysplastic Syndrome Trial in France (Onureg + Venetoclax)

Not yet recruiting
  • Untreated Myelodysplastic Syndrome
  • Onureg + Venetoclax
  • Angers, France
  • +9 more
Mar 13, 2023

Chronic Lymphocytic Leukemia, Richter Syndrome, Small Lymphocytic Lymphoma Trial in Rochester (Acalabrutinib, Durvalumab,

Recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 4, 2023

Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Duarte (Decitabine, Navitoclax, Venetoclax)

Recruiting
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Duarte, California
    City of Hope Medical Center
Aug 15, 2022

Hematopoietic and Lymphoid Cell Tumor, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Myeloid Leukemia Trial in Houston

Recruiting
  • Hematopoietic and Lymphoid Cell Neoplasm
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 31, 2022

Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Houston (Eprenetapopt, Venetoclax)

Withdrawn
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Feb 23, 2022

Follicular Lymphoma Trial in Chicago (Venetoclax, Obinutuzumab, CC-486)

Recruiting
  • Follicular Lymphoma
  • Chicago, Illinois
    University of Chicago Medical Center
Nov 12, 2021